(Reuters) -British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

London: GSK plc has announced that a supplemental New Drug Application for gepotidacin has been accepted by the US Food and ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...